Document is current
Any future updates will be listed below
-
Authors
Lieslehto, Johannes https://orcid.org/0000-0001-6030-0249
Tiihonen, Jari https://orcid.org/0000-0002-0400-6798
Ármannsdóttir, Bergný https://orcid.org/0009-0003-6376-6353
Ermis, Cagatay
Lähteenvuo, Markku https://orcid.org/0000-0002-7244-145X
Mittendorfer-Rutz, Ellenor
Tanskanen, Antti
Taipale, Heidi
-
Funding
Funding for this research was provided by:
Suomen Lääketieteen Säätiö (7709)
- License Information
-
More Information
Article History
Received: 9 October 2025
Accepted: 31 March 2026
First Online: 23 April 2026
Competing interests
: J.T., H.T., E.M.-R. and A.T. participated in research projects funded by grants from Janssen to their employing institution. J.T. has been a consultant and/or adviser to and/or has received honoraria from Eli Lilly, Evidera, HLS Therapeutics, Janssen-Cilag, Lundbeck, Mediuutiset, Orion, Otsuka, Sidera, Sunovion and WebMed Global. H.T. reports personal fees from Gedeon Richter, Janssen, Lundbeck and Otsuka. M.L. is a board member of Genomi Solutions Ltd and Springflux Ltd and has received honoraria from Sunovion, Orion Pharma, Camurus, Lundbeck, Otsuka Pharma, Recordati, Janssen and Janssen-Cilag and research funding from the Finnish Cultural Foundation and the Emil Aaltonen Foundation. The remaining authors declare no competing interests.
